Literature DB >> 23456439

Follistatin as potential therapeutic target in prostate cancer.

Maria Vittoria Sepporta1, Francesca Maria Tumminello, Carla Flandina, Marilena Crescimanno, Marco Giammanco, Maurizio La Guardia, Danila di Majo, Gaetano Leto.   

Abstract

Follistatin is a single-chain glycosylated protein whose primary function consists in binding and neutralizing some members of the transforming growth factor-β superfamily such as activin and bone morphogenic proteins. Emerging evidence indicates that this molecule may also play a role in the malignant progression of several human tumors including prostate cancer. In particular, recent findings suggest that, in this tumor, follistatin may also contribute to the formation of bone metastasis through multiple mechanisms, some of which are not related to its specific activin or bone morphogenic proteins' inhibitory activity. This review provides insight into the most recent advances in understanding the role of follistatin in the prostate cancer progression and discusses the clinical and therapeutic implications related to these findings.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23456439     DOI: 10.1007/s11523-013-0268-7

Source DB:  PubMed          Journal:  Target Oncol        ISSN: 1776-2596            Impact factor:   4.493


  96 in total

1.  Difference between follistatin isoforms in the inhibition of activin signalling: activin neutralizing activity of follistatin isoforms is dependent on their affinity for activin.

Authors:  O Hashimoto; N Kawasaki; K Tsuchida; S Shimasaki; T Hayakawa; H Sugino
Journal:  Cell Signal       Date:  2000-08       Impact factor: 4.315

2.  Plasma concentrations of angiogenesis-related molecules in patients with pancreatic cancer.

Authors:  Hiroki Sakamoto; Hideharu Kimura; Masaru Sekijima; Kazuko Matsumoto; Tokuzo Arao; Takaaki Chikugo; Yasuhide Yamada; Masayuki Kitano; Akihiko Ito; Yoshifumi Takeyama; Masatoshi Kudo; Kazuto Nishio
Journal:  Jpn J Clin Oncol       Date:  2011-12-12       Impact factor: 3.019

3.  The structure of the follistatin:activin complex reveals antagonism of both type I and type II receptor binding.

Authors:  Thomas B Thompson; Thomas F Lerch; Robert W Cook; Teresa K Woodruff; Theodore S Jardetzky
Journal:  Dev Cell       Date:  2005-10       Impact factor: 12.270

Review 4.  Follistatin and its role as an activin-binding protein.

Authors:  H Sugino; K Sugino; O Hashimoto; H Shoji; T Nakamura
Journal:  J Med Invest       Date:  1997-08

Review 5.  Signal transduction in prostate cancer progression.

Authors:  Daniel Gioeli
Journal:  Clin Sci (Lond)       Date:  2005-04       Impact factor: 6.124

6.  Dissociation of angiogenesis and tumorigenesis in follistatin- and activin-expressing tumors.

Authors:  Jelena Krneta; Jens Kroll; Frauke Alves; Claudia Prahst; Farahnaz Sananbenesi; Christian Dullin; Sarah Kimmina; David J Phillips; Hellmut G Augustin
Journal:  Cancer Res       Date:  2006-06-01       Impact factor: 12.701

Review 7.  Follistatin: a multifunctional regulatory protein.

Authors:  D J Phillips; D M de Kretser
Journal:  Front Neuroendocrinol       Date:  1998-10       Impact factor: 8.606

8.  Follistatin suppresses the production of experimental multiple-organ metastasis by small cell lung cancer cells in natural killer cell-depleted SCID mice.

Authors:  Hirokazu Ogino; Seiji Yano; Soji Kakiuchi; Hiroaki Muguruma; Kenji Ikuta; Masaki Hanibuchi; Hisanori Uehara; Kunihiro Tsuchida; Hiromu Sugino; Saburo Sone
Journal:  Clin Cancer Res       Date:  2008-02-01       Impact factor: 12.531

9.  Activin receptor signaling regulates prostatic epithelial cell adhesion and viability.

Authors:  Derek P Simon; Sivan Vadakkadath Meethal; Andrea C Wilson; Miguel J Gallego; Stephanie L Weinecke; Erin Bruce; Patrick F Lyons; Ryan J Haasl; Richard L Bowen; Craig S Atwood
Journal:  Neoplasia       Date:  2009-04       Impact factor: 5.715

10.  Tumor angiogenesis as a target for dietary cancer prevention.

Authors:  William W Li; Vincent W Li; Michelle Hutnik; Albert S Chiou
Journal:  J Oncol       Date:  2011-09-29       Impact factor: 4.375

View more
  10 in total

Review 1.  Clinical and Therapeutic Implications of Follistatin in Solid Tumours.

Authors:  Lei Shi; Jeyna Resaul; Sioned Owen; Lin Ye; Wen G Jiang
Journal:  Cancer Genomics Proteomics       Date:  2016 11-12       Impact factor: 4.069

2.  Interleukin-1-induced changes in the glioblastoma secretome suggest its role in tumor progression.

Authors:  Leonid Tarassishin; Jihyeon Lim; D Brent Weatherly; Ruth H Angeletti; Sunhee C Lee
Journal:  J Proteomics       Date:  2014-02-04       Impact factor: 4.044

3.  Co-inhibition of SMAD and MAPK signaling enhances 124I uptake in BRAF-mutant thyroid cancers.

Authors:  Kathleen A Luckett; Jennifer R Cracchiolo; Gnana P Krishnamoorthy; Luis Javier Leandro-Garcia; James Nagarajah; Mahesh Saqcena; Rona Lester; Soo Y Im; Zhen Zhao; Scott W Lowe; Elisa de Stanchina; Eric J Sherman; Alan L Ho; Steven D Leach; Jeffrey A Knauf; James A Fagin
Journal:  Endocr Relat Cancer       Date:  2021-05-18       Impact factor: 5.900

4.  Follistatin is a novel biomarker for lung adenocarcinoma in humans.

Authors:  Fangfang Chen; Ping Ren; Ye Feng; Haiyan Liu; Yang Sun; Zhonghui Liu; Jingyan Ge; Xueling Cui
Journal:  PLoS One       Date:  2014-10-27       Impact factor: 3.240

5.  Activins and their related proteins in colon carcinogenesis: insights from early and advanced azoxymethane rat models of colon cancer.

Authors:  Bassem Refaat; Adel Galal El-Shemi; Amr Mohamed Mohamed; Osama Adnan Kensara; Jawwad Ahmad; Shakir Idris
Journal:  BMC Cancer       Date:  2016-11-11       Impact factor: 4.430

6.  Follistatin is a metastasis suppressor in a mouse model of HER2-positive breast cancer.

Authors:  Darcie D Seachrist; Steven T Sizemore; Emhonta Johnson; Fadi W Abdul-Karim; Kristen L Weber Bonk; Ruth A Keri
Journal:  Breast Cancer Res       Date:  2017-06-05       Impact factor: 6.466

7.  Follistatin is a novel therapeutic target and biomarker in FLT3/ITD acute myeloid leukemia.

Authors:  Bai-Liang He; Ning Yang; Cheuk Him Man; Nelson Ka-Lam Ng; Chae-Yin Cher; Ho-Ching Leung; Leo Lai-Hok Kan; Bowie Yik-Ling Cheng; Stephen Sze-Yuen Lam; Michelle Lu-Lu Wang; Chun-Xiao Zhang; Hin Kwok; Grace Cheng; Rakesh Sharma; Alvin Chun-Hang Ma; Chi Wai Eric So; Yok-Lam Kwong; Anskar Yu-Hung Leung
Journal:  EMBO Mol Med       Date:  2020-03-05       Impact factor: 12.137

8.  Profiling Activins and Follistatin in Colorectal Cancer According to Clinical Stage, Tumour Sidedness and Smad4 Status.

Authors:  Bassem Refaat; Jamal Zekri; Akhmed Aslam; Jawwad Ahmad; Mohammed A Baghdadi; Abdelrazak Meliti; Shakir Idris; Sufian Sultan; Hosam Alardati; Haitham Akram Saimeh; Aiman Alsaegh; Mai Alhadrami; Tahira Hamid; Mohammed E Naeem; Shereef Ahmed Elsamany
Journal:  Pathol Oncol Res       Date:  2021-11-15       Impact factor: 3.201

9.  Overexpression of mir-135b and mir-210 in mesenchymal stromal cells for the enrichment of extracellular vesicles with angiogenic factors.

Authors:  Juliana Maíra Freitas Vieira; Laura Nicoleti Zamproni; Camila H C Wendt; Kildare Rocha de Miranda; Rafael Soares Lindoso; Sang Won Han
Journal:  PLoS One       Date:  2022-08-16       Impact factor: 3.752

10.  Serum Levels of Follistatin Are Positively Associated With Serum-Free Thyroxine Levels in Patients With Hyperthyroidism or Euthyroidism.

Authors:  Fen-Yu Tseng; Yen-Ting Chen; Yu-Chao Chi; Pei-Lung Chen; Wei-Shiung Yang
Journal:  Medicine (Baltimore)       Date:  2016-02       Impact factor: 1.889

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.